Eli Lilly and Co

Novo Nordisk lost $125 billion in market value due to underperformance of its experimental obesity drug CagriSema, which achieved 22.7% weight loss, below the expected 25%. This impacts Novo's ambitions for a successor to its popular Wegovy. The company plans further trials to explore CagriSema's potential.

The FDA resolved the tirzepatide shortage, granting compounders a grace period (60 days for pharmacists/physicians, 90 days for outsourcing facilities) to continue production without legal action. The shortage resolution is due to supply chain logistics, not a national shortage. Other GLP-1 RAs remain on the FDA's shortage list.

Novo Nordisk's obesity drug cagrisema, a combination of semaglutide and cagrilintide, helped patients lose up to 23% of body weight in a Phase 3 trial, falling short of the 25-27% expected by investors. The trial allowed dosing modifications, with only 57% of patients on the highest dose, suggesting tolerability concerns. Shares dropped 19% as Novo faces competition from Eli Lilly and other biotech companies in the weight-loss market.

Novo Nordisk's Ozempic (semaglutide) received EMA approval for a label expansion in Europe, indicating its ability to reduce chronic kidney disease (CKD) events in type 2 diabetes adults. Based on the Phase III FLOW trial, Ozempic showed a 24% reduction in kidney disease progression, 20% in overall mortality risk, and 18% in major cardiovascular events. This positions Ozempic as the first GLP-1 receptor agonist for CKD risk reduction, with a U.S. label expansion decision expected in 2025.

Novo Nordisk's Ozempic (semaglutide) received EMA approval for a kidney disease-related label expansion in Europe, reducing CKD events in adults with type 2 diabetes. The Phase III FLOW trial showed a 24% reduction in kidney disease progression, a 20% decrease in mortality risk, and an 18% reduction in major cardiovascular events. Ozempic is poised to be the first GLP-1 receptor agonist for this indication, with a U.S. label expansion decision expected in 2025.

Novo Nordisk's experimental diabetes and weight-loss drug CagriSema achieved 22.7% average weight loss in a phase 3 trial, falling short of the projected 25%. The drug combines semaglutide with cagrilintide, aiming for greater weight loss by mimicking multiple hormones. Despite the shortfall, 40.4% of patients achieved over 25% weight loss. Novo Nordisk stock dropped over 20% following the news, while rivals Eli Lilly and Viking Therapeutics saw stock rises.

Novo Nordisk's shares plunged 29% after its weight-loss drug, CagriSema, fell short in a key trial, losing $125 billion in market value. The drug's average weight loss of 22.7% missed the projected 25%, raising concerns amid rising competition from Eli Lilly's Zepbound. Novo Nordisk plans further trials to refine dosages and streamline production, aiming to maintain dominance in the $150 billion weight-loss drug market.

Boehringer Ingelheim and Eli Lilly's Jardiance may prevent worsening of diabetic eye disease in type 2 diabetes patients, per JAMA Ophthalmology. Analysis of over 80,000 patients showed Jardiance users had 22% lower risk of existing diabetic eye disease worsening compared to DPP4 inhibitor users. The study suggests Jardiance's potential benefit in managing diabetic retinopathy.

Novo Nordisk's CagriSema, a weight loss drug, achieved 22.7% weight loss in REDEFINE 1 trial but fell short of the 25% target, causing a stock price drop. The drug combines cagrilintide and semaglutide, with potential for further exploration.

Novo Nordisk's CagriSema obesity shot showed 20.4% weight loss over 68 weeks, falling short of the 25% target. The results align with Eli Lilly's Zepbound, while Lilly's retatrutide showed up to 24% weight loss. Novo's shares dropped 27%, erasing $120 billion in market value, while Lilly's rose 10%. Novo plans another trial to optimize doses and aims for CagriSema approval by late next year.